Keros Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

KROS$9.33+1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,
	2025	2024	2025	2024
REVENUE:
Service and other revenue	$18,168	$37	$34,059	$120
License revenue	—	—	195,355	—
Total revenue	18,168	37	229,414	120
OPERATING EXPENSES:
Research and development	(43,503)	(40,515)	(92,212)	(78,773)
General and administrative	(14,482)	(9,961)	(24,979)	(20,269)
Total operating expenses	(57,985)	(50,476)	(117,191)	(99,042)
INCOME (LOSS) FROM OPERATIONS	(39,817)	(50,439)	112,223	(98,922)
OTHER INCOME (EXPENSE), NET
Dividend income	7,120	5,378	13,912	11,184
Other expense, net	(221)	(196)	(559)	(633)
Total other income, net	6,899	5,182	13,353	10,551
Income (loss) before income taxes	(32,918)	(45,257)	125,576	(88,371)
Income tax (provision) benefit	2,222	—	(7,821)	—
Net income (loss)	$(30,696)	$(45,257)	$117,755	$(88,371)
Net income (loss) attributable to common stockholders — basic and diluted (Note 8)	$(30,696)	$(45,257)	$117,755	$(88,371)
Weighted-average shares of common stock outstanding — basic	40,612,907	36,103,187	40,586,279	35,894,305
Weighted-average shares of common stock outstanding — diluted	40,612,907	36,103,187	41,153,758	35,894,305
Net income (loss) per share of common stock — basic	$(0.76)	$(1.25)	$2.90	$(2.46)
Net income (loss) per share of common stock — diluted	$(0.76)	$(1.25)	$2.86	$(2.46)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.